Cambridge Healthtech Institute’s 23rd Annual
Cell Line Development & Engineering
Engineering Cells That Deliver
June 15-16, 2027
Cell line development is moving from random integration and extensive clone screening toward designed, predictable expression systems. The Cell Line Development & Engineering conference brings together cell line development scientists and host engineers to address the full range of expression challenges: site-specific and transposase-mediated integration, difficult-to-express proteins, multispecific chain pairing, and AAV producer cell lines. Sessions will also highlight next-generation host engineering, alternative and cell-free expression systems, and the growing role of AI/ML in predicting clone performance and long-term stability. Attendees will leave with strategies for building cell lines that are right first time, with shorter timelines, fewer clones screened, and more reliable productivity.
Coverage will include, but is not limited to:
- TARGETED, TRANSPOSASE-MEDIATED, AND NEXT-GEN INTEGRATION SYSTEMS
- Bxb1 recombinase-mediated cassette exchange landing pads
- CRISPR knock-in at genomic hot-spots
- MAR-rich landing pad engineering
- piggyBac transposon-mediated stable cell lines
- Engineered Sleeping Beauty transposase targeting
- Transposase platforms for novel/complex formats vs. site-specific integration: titer and timeline trade-offs
- Optimizing transposase-based systems and generating new transposases from different systems
- BI/MULTISPECIFICS, DIFFICULT-TO-EXPRESS PROTEINS, AAVs, AND HIGH-DENSITY CELL LINES
- Heavy/light chain expression balancing strategies
- Precise control of gene integration and stable cell line generation for multispecific antibodies
- Inducible system for difficult-to-express proteins
- O-glycan engineering
- Intensified culture conditions for high-density cell lines
- HEK293 vs. HeLa-based stable AAV producer cell lines
- AI/ML-DRIVEN CLONE SELECTION AND STABILITY PREDICTION
- GenAI/LLM-based tools enabling DNA/gene editing in cell line development
- Machine-learning clone selection and clonal stability
- Prediction of long-term stability, process robustness, titer, and product quality
- Generative AI for expression-optimized sequence design, codon, and signal peptide optimization
- Sequence-to-structure/function prediction of molecule properties
- HIGH-THROUGHPUT, AUTOMATED, AND MINIATURIZED CELL LINE DEVELOPMENT
- High-throughput clone screening
- Model-informed and automated design-of-experiments for process characterization and optimization
- Multiomics characterization of producer cell clones
- NEXT-GEN HOST ENGINEERING & GENE EDITING
- Directed CHO host evolution
- Gene knockout for new selection systems as alternatives to CHO-DG44 and CHO-GS
- Open-source CRISPR nuclease genome engineering
- Multiplex host-cell-protein knockout
- Minimizing off-target effects in CRISPR-based cell line engineering
- ALTERNATIVE HOSTS & CELL-FREE EXPRESSION
- Cell-free protein synthesis for therapeutic manufacturing
- Microbial expression systems for VHH/nanobodies and plasmids
- Advances in yeast, insect, plant, and other alternative expression systems
The deadline for priority consideration is November 20, 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation:
- To submit a podium presentation, please click here.
- To become a sponsor, click here.
- To present a poster, click here.
- To sign up to attend, click here.